StockNews.com lowered shares of NanoViricides (NYSE:NNVC – Free Report) from a hold rating to a sell rating in a research note issued to investors on Monday.
NanoViricides Trading Down 3.8 %
Shares of NYSE:NNVC opened at $1.28 on Monday. NanoViricides has a 12-month low of $1.00 and a 12-month high of $3.59. The business has a 50 day moving average of $1.45 and a two-hundred day moving average of $1.82. The company has a market capitalization of $17.85 million, a PE ratio of -1.68 and a beta of 0.96.
NanoViricides (NYSE:NNVC – Get Free Report) last posted its earnings results on Friday, September 27th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01.
Institutional Trading of NanoViricides
NanoViricides Company Profile
NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.
Read More
- Five stocks we like better than NanoViricides
- Upcoming IPO Stock Lockup Period, Explained
- Oil’s Rally Could Boost These 3 Shipping Stocks
- What is a Low P/E Ratio and What Does it Tell Investors?
- Symbotic Is Up Nearly 50% in 3 Months: Why It Can Keep Winning
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- QuantumScape: High-Risk, High-Reward Solid-State Battery Play?
Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.